Needham & Company
-
Selecta Biosciences (SELB) PT Raised to $7 at Needham & Company
-
Selecta Biosciences to Participate at the 20th Annual Needham Healthcare Conference
-
Selecta Biosciences to Present at the 19th Annual Needham Virtual Healthcare Conference
-
Companies with NDRs 3/26
-
Selecta Biosciences (SELB) PT Lowered to $9 at Needham & Company
-
Selecta Biosciences to Present at the Needham & Company 18th Annual Healthcare Conference April 9, 2019
-
Selecta Biosciences (SELB) PT Lowered to $12 at Needham & Company
-
Selecta Biosciences (SELB) Prices 20M Share Common Offering at $1.50/Sh
-
Selecta Biosciences Announces Pricing of Public Offering of Common Stock
-
Selecta Biosciences (SELB) to Offer Common Stock
-
Selecta Biosciences Announces Proposed Public Offering of Common Stock
-
Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018
-
Selecta Biosciences (SELB) Sell-Off 'Greatly Overdone' - Needham & Company
-
Selecta Biosciences to Present at the Needham Healthcare Conference on April 4, 2017
-
Needham & Company Reiterates Buy Rating and $28 PT on Selecta Biosciences (SELB) Following 'Very Promising' Initial SEL-212 Phase2 Data
-
Needham & Company Starts Selecta Biosciences (SELB) at Buy
-
Selecta Biosciences Announces Closing of Initial Public Offering
-
Selecta Biosciences (SELB) IPO Opens, Trades Modestly Higher
-
Selecta Biosciences (SELB) Prices Common Stock IPO at $14/Share, at Low-End of Range
-
Selecta Biosciences Announces Pricing of Initial Public Offering